Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 4, July-August, p. 561–568

Publication type: review article

Language: English

Superoxide Dismutase as a Potential Therapeutic Agent

Dysmutaza ponadtlenkowa jako potencjalny czynnik terapeutyczny

Michał Skrzycki1,, Hanna Czeczot1,

1 Department of Biochemistry Medical University of Warsaw, Poland

Abstract

Superoxide dismutase (SOD) is a major antioxidative enzyme and the only one that neutralizes superoxide ion, a precursor of reactive oxygen species (ROS) and their reactive derivatives. ROS can cause considerable damage to biological systems and are implicated in many pathologies, e.g. neurodegenerative diseases, tumors, atherosclerosis, hypertension, and diabetes. This paper presents a history of the discovery of superoxide dismutase and the functions of particular SOD isoforms in the organism. It also describes the possibilities of their use in the treatment of free−radical−based diseases.

Streszczenie

Dysmutaza ponadtlenkowa (SOD) jest głównym i jedynym enzymem antyoksydacyjnym, który unieczynnia w komórkach anionorodnik ponadtlenkowy – prekursor wolnych rodników tlenowych (w.r.t.) i ich reaktywnych pochodnych. Skutki działania w.r.t. prowadzą do rozwoju wielu patologii (chorób neurodegeneracyjnych, nowotworów, miażdżycy, nadciśnienia, cukrzycy i innych). W artykule przedstawiono historię odkrycia dysmutazy ponadtlenkowej i funkcje, jakie pełnią poszczególne izoenzymy SOD w organizmie, omówiono także możliwości ich zastosowania w terapii chorób o podłożu wolnorodnikowym.

Key words

superoxide dismutase, oxidative stress, enzymatic therapy, SOD mimetics

Słowa kluczowe

dysmutaza ponadtlenkowa, stres oksydacyjny, terapia enzymatyczna, mimetyki SOD

References (71)

  1. Mann T, Keilin D: Haemocuprein and hepatocuprein, copper protein compounds of blood and liver in mammals. Proc R Soc Ser B 1938, 126, 303–315.
  2. Carrico RJ, Deutsch HF: Isolation of human hepatocuprein and cerebrocuprein. Their identity with erytrocuprein. J Biol Chem 1969, 244, 6087–6093.
  3. Huber W, Schule TL, Carson S, Goldhamer RE, Vogin EE: Some chemical and pharmacologic properties of a novel anti−inflammatory protein. Toxicol Appl Pharmacol 1968, 12, 308.
  4. McCord JM, Fridovich I: Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969, 244, 6049–6055.
  5. Pauling L: The discovery of superoxide radical. Trends Biochem Sci 1979, 4, N270–N271.
  6. Babior BM, Kipnes RS, Curnutte JT: Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 1973 52, 741–744.
  7. McCord JM: Free radicals and inflammation: Protection of synovial fluid by superoxide dismutase. Science 1974, 185, 529–531.
  8. Keele BB, McCord JM, Fridovich I: Superoxide dismutase from Escherichia coli B. A new manganese−containing enzyme. J Biol Chem 1970, 245, 6176–6181.
  9. Weisiger RA, Fridovich I: Mitochondrial superoxide simutase. Site of synthesis and intramitochondrial localization. J Biol Chem 1973, 248, 4793–4796.
  10. Yost FJ, Fridovich I: An iron−containing superoxide dismutase from Escherichia coli. J Biol Chem 1973, 248, 4905–4908.
  11. Marklund SL, Holme E, Hellner L: Superoxide dismutase in extracellular fluids. Clin Chim Acta 1982, 126, 41–51.
  12. Fridovich I: Superoxide anion radical (O2 –), superoxide dismutases, and related matters. J Biol Chem 1997, 272, 18515–18517.
  13. Zelko IN, Mariani TJ, Folz RJ: Superoxide dismutase multigene family: A comparison of the Cu,ZnSOD (sod1), Mn−SOD (sod2), and EC−SOD (sod3) gene structures, evolution, and expression. Free Radic Biol Med 2002, 33, 337–349.
  14. Beckman KB, Ames BN: Endogenous oxidative damage of mtDNA. Mutat Res 1999, 424, 51–58.
  15. Isoherranen K, Peltola V, Laurikainen L, Punnonen J, Laihia J, Ahotupa M, Punnonen K: Regulation of copper/zinc and manganese superoxide dismutase by UVB irradiation, oxidative stress and cytokines. J Photochem Photobiol 1997, B 40, 288–293.
  16. Fattman CL, Schafter M, Oury TD: Extracellular superoxide dismutase in biology and medicine. Free Radic Biol Med 2003, 35, 226–256.
  17. Antunes F, Cadenas E: Cellular titration of apoptosis with steady state concentrations of H2O2: submicromolar levels of H2O2 induce apoptosis through Fenton chemistry independent of the cellular thiol state. Free Radic Biol Med 2001, 30, 1008–1018.
  18. Szatrowski TP, Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991, 51, 794–798.
  19. Casado A, de laTorre R, Lopez−Fernandez EM, Carrascosa D, Casado CM, Ramirez VM: Superoxide dismutase and catalase blood levels in patients with malignant diseases. Cancer Lett 1995, 93, 187–192.
  20. Oberley TD, Oberley LW: Antioxidant enzyme levels in cancer. Histol Histopathol 1997, 12, 525–535.
  21. Gate L, Paul J, Nguyen−Ba G, Tew KD, Tapiero H: Oxidative stress induced in pathologies: the role of antioxidants. Biomed Pharmacother 1999, 53, 169–180.
  22. Ciolino HP, Levine RL: Modification of proteins in endothelial cell death during oxidative stress. Free Radic Biol Med 1997, 22, 1277–1282.
  23. Halliwell B, Chirico S: Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 1993, 57 (Suppl.), 715–724.
  24. Dominguez A: Modifying superoxide dismutase for improved biopharmaceutical properties. Biotechnol Apl 2006, 23, 17–21.
  25. Bartosz G: Druga twarz tlenu. Wolne rodniki w przyrodzie. Wydawnictwo Naukowe PWN, Warszawa 2003, wyd. 2.
  26. Nguyen KT, West JL: Photopolymerizable hydrogels for tissue engineering applications. Biomaterials 2002, 23, 4307–4314.
  27. Ng TB, Gao W, Li L, Niu SM, Zhao L, Liu J, Shi LS, Fu M, Liu F: Rose (Rosa rugosa)−flower extract increases the activities of antioxidant enzymes and their gene expression and reduces lipid peroxidation. Biochem Cell Biol 2005, 83 (1), 78–85.
  28. Izumi M, McDonald MC, Sharpe MA, Chatterjee PK, Thiemermann C: Superoxide dismutase mimetics with catalase activity reduce the organ injury in hemorrhagic shock. Shock 2002, 18, 230–235.
  29. Pong K, Rong Y, Doctrow SR, Baudry M: Attenuation of zinc−induced intracellular dysfunction and neurotoxicity by a synthetic superoxide dismutase/catalase mimetic, in cultured cortical neurons. Brain Res 2002, 950, 218–230.
  30. Johnson F, Giulivi C: Superoxide dismutases and their impact upon human health. Mol Asp Med 2005, 26, 340–352.
  31. Umemoto S, Tanaka M, Kawahara S, Kubo M, Umeji K, Hashimoto R, Matsuzaki M: Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke−prone spontaneously hypertensive rats. Hypertens Res 2004, 27, 877–885.
  32. Buter H, Navis GY, Woittiez AJ, de Zeeuw D, de Jong PE: Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Eur J Clin Pharmacol 1999, 54, 953–958.
  33. Pizzi C, Manfrini O, Fontana F, Bugiardini R: Angiotensin−converting enzyme inhibitors and 3−hydroxy−3− −methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity. Circulation 2004, 109, 53–58.
  34. Sleight PJ: The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000, (1), 18–20.
  35. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin−converting−enzyme inhibitor, ramipril, on cardiovascular events in high−risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342, 145–153.
  36. Hoogwerf BJ, Young JB: The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not. Cleve Clin J Med 2000, 67, 287–293.
  37. Muscoli C, Cuzzocrea S, Riley DP, Zweier JL, Thiemermann C, Wang ZQ, Salvemini D: On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol 2003, 140, 445–460.
  38. Maksimienko AV, Bezrukavnikova LM, Grigorieva EL, Yaglov VV, Torchilin VP: Effect of native and modified forms of superoxide dismutase and catalase on experimental silicosis in rats. Ann NY Acad Sci 1992, 672, 118–125.
  39. Mao GD, Thomas PD, Lopaschuk GD, Poznansky MJ: Superoxide dismutase (SOD)−catalase conjugates. Role of hydrogen peroxide and the Fenton reaction in SOD toxicity. J Biol Chem 1993, 268, 416–420.
  40. Gao B, Flores SC, Leff JA, Bose SK, McCord JM: Synthesis and anti−inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3. Am J Physiol Lung Cell Mol Physiol 2003, 284, L917–L925.
  41. Hernandez−Saavedra D, Zhou H, McCord JM: Anti−inflammatory properties of a chimeric recombinant superoxide dismutase: SOD2/3. Biomed Pharmacoter 2005, 59, 204–208.
  42. Closa D, Bulbena O, Rosello−Catafau J, Fernandez−Cruz L, Gelpi E: Effect of prostaglandin and superoxide dismutase administration on oxygen free radical production in experimental acute pancreatitis. Inflammation 1993, 17, 563–571.
  43. Hartung HP, Schafer B, Heininger K, Toyka KV: Suppression of experimental autoimmune neuritis by the oxygen radical scavengers superoxide dismutase and catalase. Ann Neurol 1988, 23, 453–460.
  44. Liu TH, Beckman JS, Freeman BA, Hogan EL, Hsu CY: Polyethylene glycol−conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol 1989, 256, H589–H593.
  45. Pfister HW, Koedel U, Lorenzl S, Tomasz A: Antioxidants attenuate microvascular changes in the early phase of experimental pneumococcal meningitis in rats. Stroke 1992, 23, 1798–1804.
  46. Manson PN, Anthenelli RM, Im MJ, Bulkley GB, Hoopes JE: The role of oxygen−free radicals in ischemic tissue injury in island skin flaps. Ann Surg 1983, 198, 87–90.
  47. Tang G, White JE, Gordon RJ, Lumb PD, Tsan MF: Polyethylene glycol−conjugated superoxide dismutase protects rats against oxygen toxicity. J Appl Physiol 1993, 74, 1425–1431.
  48. Veronese FM, Caliceti P, Schiavon O, Sergi M: Polyethylene glycol−superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev 2002, 54, 587–606.
  49. Swart PJ, Hirano T, Kuipers ME, Ito Y, Smit C, Hashida M, Nishikawa M, Beljaars K, Meijer DK, Poelstra K: Targeting of superoxide dismutase to the liver results in antiinflammatory effects in rats with fibrotic livers. J Hepatol 1999, 31, 1034–1043.
  50. Hirano T, Todoroki T, Morita R, Kato S, Ito Y, Kim K, Shukla PG, Veronese F, Maeda H, Ohashi S: Antiinflammatory effect of the conjugate of superoxide dismutase with the copolymer of divinyl ether and maleic anhydride against rat re−expansion pulmonary edema. J Control Release 1997, 48, 131–139.
  51. Vorauer−Uhl K, Furnschlief E, Wagner A, Ferko B, Katinger H: Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation. Eur J Pharm Sci 2001, 14, 63–67.
  52. McIntyre M, Bohr DF, Dominiczak AF: Endothelial function in hypertension: the role of superoxide anion. Hypertension 1999, 34, 539–545.
  53. Connor HD, Gao W, Nukina S, Lemasters JJ, Mason RP, Thurman RG: Evidence that free radicals are involved in graft failure following orthotopic liver transplantation in the rat – an electron paramagnetic resonance spin trapping study. Transplantation 1992, 54, 199–204.
  54. Koo DD, Welsh KI, West NE, Channon KM, Penington AJ, Roake JA, Morris PJ, Fuggle SV: Endothelial cell protection against ischemia/reperfusion injury by lecithinized superoxide dismutase. Kidney Int 2001, 60, 786–796.
  55. Orsi NM, Leese HJ: Protection against reactive oxygen species during mouse preimplantation embryo development: role of EDTA, oxygen tension, catalase, superoxide dismutase and pyruvate. Mol Reprod Dev 2001, 59, 44–53.
  56. Suresh A, Guedez L, Moreb J, Zucali J: Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment. Br J Haematol 2003, 120, 457–463.
  57. Flohe L: Superoxide dismutase for therapeutic use: clinical experience, dead ends and hopes. Mol Cell Biochem 1988, 84, 123–131.
  58. Emerit J, Pelletier S, Likforman J, Pasquier C, Thuilier A: Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in the treatment of Crohn’s disease. Free Radic Res Commun 1991, 12–13, 563–569.
  59. Riedl CR, Sternig P, Galle G, Langmann F, Vcelar B, Vorauer K, Wagner A, Katinger H, Pfluger H: Liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized placebo−controlled double−blind prospective clinical study. Eur Urol 2005, 48, 656–661.
  60. Shimmura S, Igarashi R, Yaguchi H, Ohashi Y, Shimazaki J, Tsubota K: Lecithin−bound superoxide dismutase in the treatment of noninfectious corneal ulcers. Am J Ophthalmol 2003, 135, 613–619.
  61. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W; North American Recombinant Human CuZnSOD Study Group: Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003, 111, 469–476.
  62. Jobe AH: An Unanticipated Benefit of the Treatment of Preterm Infants With CuZn Superoxide Dismutase. Pediatrics 2003, 111, 680.
  63. Xia XG, Zhou H, Zhou S, Yu Y, Wu R, Xu Z: An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase. J Neurochem. 2005, 92, 362–367.
  64. Karlsson K, Sandstrom J, Edlund A, Marklund SL: Turn−over of extracellular superoxide dismutase in tissues. Lab Invest 1994, 70, 705–710.
  65. Stromqvist M, Houdebine M, Andersson JO, Edlund A, Johansson T, Viglietta C, Puissant C, Hansson L: Recombinant human extracellular superoxide dismutase produced in milk of transgenic rabbits. Transgenic Res 1997, 6, 271–278.
  66. Li Q, Bolli R, Qiu Y, Tang XL, Murphree SS, French BA: Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits. Circulation 1998, 98, 1438–1448.
  67. Iyama S, Okamoto T, Sato T, Yamauchi N, Sato Y, Sasaki K, Takahashi M, Tanaka M, Adachi T, Kogawa K, Kato J, Sakamaki S, Niitsu Y: Treatment of murine collagen−induced arthritis by ex vivo extracellular superoxide dismutase gene transfer. Arthritis Rheum 2001, 44, 2160–2167.
  68. Nakane H, Chu Y, Faraci FM, Oberley LW, Heistad DD: Gene transfer of extracellular superoxide dismutase increases superoxide dismutase activity in cerebrospinal fluid. Stroke 2001, 32, 184–189.
  69. Li Q, Bolli R., Yumin Qiu, Xian−Liang Tang, Yiru Guo, French BA: Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infraction. Circulation 2001, 103, 1893–1898.
  70. Lund DD, Gunnett CA, Chu Y, Brooks RM, Faraci FM, Heistad DD: Gene transfer of extracellular superoxide dismutase improves relaxation of aorta after treatment with endotoxin. Am J Physiol Heart Circ Physiol 2004, 287, H805–H811.
  71. Laukkanen MO, Leppanen P, Turunen P, Tuomisto T, Naarala J, Yla−Herttuala S: EC−SOD gene therapy reduces paracetamol−induced liver damage in mice. J Gene Med 2001, 3, 321–325.
© Wroclaw Medical University